Charles River Laboratories International, Inc. (CRL) P/E Ratio History
Deep ValueTrading at -62.4x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2001–2024
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Charles River Laboratories International, Inc. (CRL) trades at a price-to-earnings ratio of -62.4x, with a stock price of $181.56 and trailing twelve-month earnings per share of $-3.77.
The current P/E is 168% below its 5-year average of 91.5x. Over the past five years, CRL's P/E has ranged from a low of 20.9x to a high of 1230.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CRL trades at a 382% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, CRL trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CRL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CRL Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CRL P/E vs Peers
Contract Research and Preclinical Services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $28B | 21.4Lowest | 0.53Best | +5% | |
| $13B | 29.8 | 0.95 | +21%Best | |
| $11B | 48.5 | - | -70% | |
| $1B | 24.8 | - | -4% | |
| $5B | 31.3 | - | -52% | |
| $21B | 24.3 | - | +18% | |
| $8B | 26.9 | 1.17 | -25% | |
| $172B | 26.2 | 12.40 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CRL Historical P/E Data (2001–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | - | $184.60 | $0.15 | 1230.7x | +1470% |
| FY2024 Q3 | Sep 28 2024 | $198.31 | $7.99 | 24.8x | -68% |
| FY2024 Q2 | Jun 29 2024 | $206.58 | $8.35 | 24.7x | -68% |
| FY2024 Q1 | Mar 30 2024 | $270.95 | $8.50 | 31.9x | -59% |
| FY2023 Q4 | Dec 31 2023 | $236.40 | $9.21 | 25.7x | -67% |
| FY2023 Q3 | Sep 30 2023 | $195.98 | $9.24 | 21.2x | -73% |
| FY2023 Q2 | Jul 01 2023 | $210.25 | $9.43 | 22.3x | -72% |
| FY2023 Q1 | Apr 01 2023 | $201.82 | $9.67 | 20.9x | -73% |
| FY2022 Q4 | Dec 31 2022 | $217.90 | $9.47 | 23.0x | -71% |
| FY2022 Q3 | Sep 24 2022 | $187.51 | $8.49 | 22.1x | -72% |
| FY2022 Q2 | Jun 25 2022 | $226.32 | $8.62 | 26.3x | -67% |
| FY2022 Q1 | Mar 26 2022 | $279.10 | $8.21 | 34.0x | -57% |
| FY2021 Q4 | Dec 31 2021 | $376.78 | $7.60 | 49.6x | -37% |
| FY2021 Q3 | Sep 25 2021 | $458.30 | $7.74 | 59.2x | -24% |
| FY2021 Q2 | Jun 26 2021 | $367.90 | $7.76 | 47.4x | -40% |
| FY2021 Q1 | Mar 27 2021 | $288.04 | $7.38 | 39.0x | -50% |
| FY2020 Q4 | - | $249.86 | $7.20 | 34.7x | -56% |
| FY2020 Q3 | Sep 26 2020 | $216.77 | $6.00 | 36.1x | -54% |
| FY2020 Q2 | Jun 27 2020 | $169.98 | $5.43 | 31.3x | -60% |
| FY2020 Q1 | Mar 28 2020 | $126.23 | $4.97 | 25.4x | -68% |
| FY2019 Q4 | - | $152.76 | $5.06 | 30.2x | -61% |
| FY2019 Q3 | Sep 28 2019 | $132.62 | $4.66 | 28.5x | -64% |
| FY2019 Q2 | Jun 29 2019 | $141.90 | $4.42 | 32.1x | -59% |
| FY2019 Q1 | Mar 30 2019 | $145.25 | $4.64 | 31.3x | -60% |
| FY2018 Q4 | Dec 31 2018 | $113.18 | $4.61 | 24.6x | -69% |
| FY2018 Q3 | Sep 29 2018 | $134.54 | $2.77 | 48.6x | -38% |
| FY2018 Q2 | Jun 30 2018 | $112.26 | $2.63 | 42.7x | -46% |
| FY2018 Q1 | Mar 31 2018 | $106.74 | $2.65 | 40.3x | -49% |
| FY2017 Q4 | Dec 31 2017 | $109.45 | $2.54 | 43.1x | -45% |
| FY2017 Q3 | Sep 30 2017 | $108.02 | $4.10 | 26.3x | -66% |
| FY2017 Q2 | Jul 01 2017 | $101.15 | $3.81 | 26.5x | -66% |
| FY2017 Q1 | Apr 01 2017 | $89.95 | $3.42 | 26.3x | -66% |
| FY2016 Q4 | Dec 31 2016 | $76.19 | $3.23 | 23.6x | -70% |
| FY2016 Q3 | Sep 24 2016 | $82.76 | $2.97 | 27.9x | -64% |
| FY2016 Q2 | Jun 25 2016 | $80.35 | $2.97 | 27.1x | -65% |
| FY2016 Q1 | Mar 26 2016 | $74.33 | $3.26 | 22.8x | -71% |
| FY2015 Q4 | - | $80.39 | $3.14 | 25.6x | -67% |
| FY2015 Q3 | Sep 26 2015 | $64.70 | $3.04 | 21.3x | -73% |
| FY2015 Q2 | Jun 27 2015 | $71.69 | $2.93 | 24.5x | -69% |
| FY2015 Q1 | Mar 28 2015 | $79.61 | $2.65 | 30.0x | -62% |
| FY2014 Q4 | Dec 31 2014 | $63.64 | $2.66 | 23.9x | -69% |
| FY2014 Q3 | Sep 27 2014 | $59.64 | $2.49 | 24.0x | -69% |
| FY2014 Q2 | Jun 28 2014 | $52.72 | $2.45 | 21.5x | -73% |
| FY2014 Q1 | Mar 29 2014 | $59.39 | $2.27 | 26.2x | -67% |
| FY2013 Q4 | - | $53.04 | $2.13 | 24.9x | -68% |
| FY2013 Q3 | Sep 28 2013 | $46.25 | $2.11 | 21.9x | -72% |
| FY2013 Q2 | Jun 29 2013 | $41.03 | $1.93 | 21.3x | -73% |
| FY2013 Q1 | Mar 30 2013 | $44.27 | $2.00 | 22.1x | -72% |
| FY2012 Q4 | Dec 31 2012 | $37.47 | $2.01 | 18.6x | -76% |
| FY2012 Q3 | Sep 29 2012 | $39.60 | $2.19 | 18.1x | -77% |
| FY2012 Q2 | Jun 30 2012 | $32.76 | $2.10 | 15.6x | -80% |
| FY2012 Q1 | Mar 31 2012 | $36.09 | $2.10 | 17.2x | -78% |
| FY2011 Q4 | Dec 31 2011 | $27.33 | $2.13 | 12.8x | -84% |
| FY2010 Q3 | Sep 25 2010 | $32.36 | $0.37 | 87.5x | +12% |
| FY2010 Q2 | Jun 26 2010 | $35.44 | $1.32 | 26.8x | -66% |
| FY2010 Q1 | Mar 27 2010 | $39.20 | $1.62 | 24.2x | -69% |
| FY2009 Q4 | - | $33.69 | $1.74 | 19.4x | -75% |
| FY2008 Q3 | Sep 27 2008 | $58.04 | $2.49 | 23.3x | -70% |
| FY2008 Q2 | Jun 28 2008 | $64.03 | $2.47 | 25.9x | -67% |
| FY2008 Q1 | Mar 29 2008 | $58.34 | $2.32 | 25.1x | -68% |
| FY2007 Q4 | Dec 31 2007 | $65.80 | $2.23 | 29.5x | -62% |
| FY2007 Q3 | Sep 29 2007 | $56.15 | $2.23 | 25.2x | -68% |
| FY2007 Q2 | Jun 30 2007 | $51.62 | $1.37 | 37.7x | -52% |
| FY2007 Q1 | Mar 31 2007 | $46.26 | $1.18 | 39.2x | -50% |
| FY2006 Q2 | Jul 01 2006 | $36.80 | $0.12 | 306.7x | +291% |
| FY2006 Q1 | Apr 01 2006 | $49.02 | $0.20 | 245.1x | +213% |
| FY2005 Q4 | Dec 31 2005 | $42.37 | $1.97 | 21.5x | -73% |
| FY2005 Q3 | Sep 24 2005 | $43.39 | $1.58 | 27.5x | -65% |
| FY2005 Q2 | Jun 25 2005 | $47.95 | $1.65 | 29.1x | -63% |
| FY2005 Q1 | Mar 26 2005 | $47.80 | $1.73 | 27.6x | -65% |
| FY2004 Q4 | Dec 31 2004 | $46.01 | $1.69 | 27.2x | -65% |
| FY2004 Q3 | Sep 25 2004 | $46.01 | $1.79 | 25.7x | -67% |
| FY2004 Q2 | Jun 26 2004 | $47.25 | $1.68 | 28.1x | -64% |
| FY2004 Q1 | Mar 27 2004 | $42.51 | $1.58 | 26.9x | -66% |
| FY2003 Q4 | Dec 31 2003 | $34.33 | $1.62 | 21.2x | -73% |
| FY2003 Q3 | Sep 27 2003 | $30.90 | $1.53 | 20.2x | -74% |
| FY2003 Q2 | Jun 28 2003 | $32.63 | $1.51 | 21.6x | -72% |
| FY2003 Q1 | Mar 29 2003 | $26.11 | $1.43 | 18.3x | -77% |
| FY2002 Q4 | - | $38.48 | $0.98 | 39.1x | -50% |
| FY2002 Q3 | Sep 28 2002 | $38.50 | $0.86 | 44.5x | -43% |
| FY2002 Q2 | Jun 29 2002 | $35.05 | $0.71 | 49.0x | -37% |
| FY2002 Q1 | Mar 30 2002 | $31.00 | $0.58 | 53.0x | -32% |
| FY2001 Q4 | Dec 31 2001 | $33.48 | $0.80 | 41.9x | -47% |
| FY2001 Q3 | Sep 29 2001 | $35.37 | $0.72 | 49.1x | -37% |
| FY2001 Q1 | Mar 31 2001 | $24.75 | $0.01 | 2475.0x | +3057% |
Average P/E for displayed period: 78.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRL — Frequently Asked Questions
Quick answers to the most common questions about buying CRL stock.
What is CRL's P/E ratio?
Charles River Laboratories International, Inc. (CRL) trailing twelve-month P/E ratio is -62.4x, based on TTM diluted EPS of $-3.77. The 5-year average P/E is 91.5x and the historical range spans 20.9x to 1230.7x.
Is CRL stock overvalued or undervalued?
CRL trades at -62.4x P/E, below its 5-year average of 91.5x. At the 0th percentile of its historical range (20.9x–1230.7x), the stock is priced at a discount to its own history.
Is CRL stock expensive?
No, CRL is not expensive on a historical basis. The current P/E of -62.4x is below the 5-year average of 91.5x and sits at the 0th percentile of its valuation range.
What is CRL's historical P/E range?
Over the past 5 years, CRL's P/E ratio has ranged from 20.9x to 1230.7x, with a median of 31.3x and an average of 91.5x. The current P/E of -62.4x places the stock at the 0th percentile of this range. Full historical data spans 2001–2024.
How does CRL's P/E compare to the S&P 500?
CRL trades at -62.4x P/E versus the S&P 500 median of 24.3x. The 357% discount to the market suggests lower growth expectations or perceived higher risk.
How does CRL's valuation compare to Healthcare peers?
Charles River Laboratories International, Inc. P/E of -62.4x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CRL's PEG ratio?
CRL PEG ratio is N/A, based on a P/E of -62.4x and EPS growth of -1555.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CRL's earnings yield?
CRL earnings yield is N/A, the inverse of its -62.4x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.